Accession Number: | 0001104659-21-095512 |
Date: | 2021-07-21 |
Issuer: | LIQUIDIA CORP (LQDA) |
Original Submission Date: |
SHAH TUSHAR
419 DAVIS DRIVE, SUITE 100
MORRISVILLE, NC 27560
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 2.54 | 2021-07-21 | deemed execution date | A | 10,000 (a) | 2031-07-21 | common stock 10,000 | $2.54 | 10,000 | direct |
ID | footnote |
---|---|
f1 | the option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on july 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon u.s. food and drug administration (fda) tentative approval of the issuer's new drug application for liq861. |